Surface chemical company AnteoTech will procure a test strip manufacturing line allowing it to begin production of its EuGeni SARS-CoV-2 antigen rapid diagnostic test (pictured) in Brisbane in early 2022.
The new facility will provide an extra 12 million test strips pert annum capacity, bringing total strip production capacity for the Anteo Group to 32 million a year.
Announcing its lateral flow rapid test manufacturing strategy, the company said in-house manufacture would speed time to market as new tests were developed, eliminating technology transfer steps to outside manufacturers which normally take up to eight months.
The new plant at Eight Mile Plains will incorporate strip manufacture in which antibody or antigen macromolecules and its AnteoBind activated particles are applied, as well as assembly and kit packaging including pre-filling of chemicals into buffer bottles.
It will improve the efficiency of cassette assembly and packaging which is a time, capital and labour-intensive process.
“Further lateral flow strip production capability will be introduced as demand increases over time and the locations for these additional machines will be decided based on market need.
“AnteoTech’s strategy is to engage with cassette and kit assembly partners in Europe, Mid-Asia Australia and North America and utilise these facilities as demand increases.”
AnteoTech’s test kits are currently assembled in Europe by Operon.
Subscribe to our free @AuManufacturing newsletter here.